Advice

following a full submission

tofacitinib (Xeljanz) is accepted for use within NHSScotland.

Indication under review: For the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent.

In phase III studies, tofacitinib was superior to placebo in achieving and sustaining remission in adult patients with moderately to severely active ulcerative colitis who had treatment failure with, or were intolerant to, a conventional or biologic medicine.

This SMC advice takes account of the benefits of a Patient Access Scheme (PAS) that improves the cost-effectiveness of tofacitinib. This advice is contingent upon the continuing availability of the PAS in NHS Scotland or a list price that is equivalent or lower.

 

 

 

Medicine details

Medicine name:
tofacitinib (Xeljanz)
SMC ID:
SMC2122
Indication:
For the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, lost response, or were intolerant to conventional therapy or a biologic agent
Pharmaceutical company
Pfizer Ltd
BNF chapter
Gastro-intestinal system
Submission type
Full
Status
Accepted
Date advice published:
11 February 2019